Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB

Jae Yeo Park, Min Ja Jang, Yoon Hee Chung, Kyung Yong Kim, Sung Su Kim, Won Bok Lee, Seungkwon You, Youn Seok Choi, Dae Young Hur, Daejin Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Chemotherapy agents have adverse immunotherapeutic effects secondary to inhibition of hematopoietic stem cell proliferation, particularly in committed lymphoblast. Certain anti-cancer drugs have immuno-modulatory properties, although mechanisms are still not fully understood. In the current study, we explored the effects of doxorubicin on peripheral blood CD4+ and CD8+ T-cell responses pre- and post-stimulation. Doxorubicin treatment alone had no effects on peripheral blood T lymphocytes and regulatory T-cells in vivo and in vitro. However, CD4+ T-cells were resistant to doxorubicin and demonstrated more robust proliferation than CD8+ T-cells after doxorubicin pre-treatment. CD40 ligand and 4-1BB expression on the surface of CD4+ T-cells were increased after TCR-ligation activation; however, expression on CD8+ T-cells was not increased. Dendritic cells cultured in the presence of activated CD4+ T-cells pre-treated with doxorubicin had greater survival rates than those cultured with activated CD8+ T-cells. Doxorubicin pre-treatment followed by anti-CD3ε + anti-4-1BB activation led to proliferation of CD4+ T-cells and no proliferative effects on CD8+ T-cells. Our results collectively suggest that doxorubicin pre-treatment in cancer patients may be a more effective way to enhance anti-cancer immune responses by increased antigen-specific CD4+ Th1 immune responses.

Original languageEnglish
Pages (from-to)1530-1539
Number of pages10
JournalInternational Immunopharmacology
Volume9
Issue number13-14
DOIs
Publication statusPublished - 2009 Dec 1

Fingerprint

CD40 Ligand
Doxorubicin
T-Lymphocytes
Neoplasms
Histocompatibility Antigens Class II
Regulatory T-Lymphocytes
Therapeutics
Hematopoietic Stem Cells
Dendritic Cells
Ligation
Survival Rate
Cell Proliferation
Drug Therapy

Keywords

  • 4-1BB
  • CD4
  • CD40 ligand
  • Doxorubicin

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Park, J. Y., Jang, M. J., Chung, Y. H., Kim, K. Y., Kim, S. S., Lee, W. B., ... Kim, D. (2009). Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB. International Immunopharmacology, 9(13-14), 1530-1539. https://doi.org/10.1016/j.intimp.2009.09.008

Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB. / Park, Jae Yeo; Jang, Min Ja; Chung, Yoon Hee; Kim, Kyung Yong; Kim, Sung Su; Lee, Won Bok; You, Seungkwon; Choi, Youn Seok; Hur, Dae Young; Kim, Daejin.

In: International Immunopharmacology, Vol. 9, No. 13-14, 01.12.2009, p. 1530-1539.

Research output: Contribution to journalArticle

Park, JY, Jang, MJ, Chung, YH, Kim, KY, Kim, SS, Lee, WB, You, S, Choi, YS, Hur, DY & Kim, D 2009, 'Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB', International Immunopharmacology, vol. 9, no. 13-14, pp. 1530-1539. https://doi.org/10.1016/j.intimp.2009.09.008
Park, Jae Yeo ; Jang, Min Ja ; Chung, Yoon Hee ; Kim, Kyung Yong ; Kim, Sung Su ; Lee, Won Bok ; You, Seungkwon ; Choi, Youn Seok ; Hur, Dae Young ; Kim, Daejin. / Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB. In: International Immunopharmacology. 2009 ; Vol. 9, No. 13-14. pp. 1530-1539.
@article{75c9e81d00724b2385a4f76555b24983,
title = "Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB",
abstract = "Chemotherapy agents have adverse immunotherapeutic effects secondary to inhibition of hematopoietic stem cell proliferation, particularly in committed lymphoblast. Certain anti-cancer drugs have immuno-modulatory properties, although mechanisms are still not fully understood. In the current study, we explored the effects of doxorubicin on peripheral blood CD4+ and CD8+ T-cell responses pre- and post-stimulation. Doxorubicin treatment alone had no effects on peripheral blood T lymphocytes and regulatory T-cells in vivo and in vitro. However, CD4+ T-cells were resistant to doxorubicin and demonstrated more robust proliferation than CD8+ T-cells after doxorubicin pre-treatment. CD40 ligand and 4-1BB expression on the surface of CD4+ T-cells were increased after TCR-ligation activation; however, expression on CD8+ T-cells was not increased. Dendritic cells cultured in the presence of activated CD4+ T-cells pre-treated with doxorubicin had greater survival rates than those cultured with activated CD8+ T-cells. Doxorubicin pre-treatment followed by anti-CD3ε + anti-4-1BB activation led to proliferation of CD4+ T-cells and no proliferative effects on CD8+ T-cells. Our results collectively suggest that doxorubicin pre-treatment in cancer patients may be a more effective way to enhance anti-cancer immune responses by increased antigen-specific CD4+ Th1 immune responses.",
keywords = "4-1BB, CD4, CD40 ligand, Doxorubicin",
author = "Park, {Jae Yeo} and Jang, {Min Ja} and Chung, {Yoon Hee} and Kim, {Kyung Yong} and Kim, {Sung Su} and Lee, {Won Bok} and Seungkwon You and Choi, {Youn Seok} and Hur, {Dae Young} and Daejin Kim",
year = "2009",
month = "12",
day = "1",
doi = "10.1016/j.intimp.2009.09.008",
language = "English",
volume = "9",
pages = "1530--1539",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "13-14",

}

TY - JOUR

T1 - Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB

AU - Park, Jae Yeo

AU - Jang, Min Ja

AU - Chung, Yoon Hee

AU - Kim, Kyung Yong

AU - Kim, Sung Su

AU - Lee, Won Bok

AU - You, Seungkwon

AU - Choi, Youn Seok

AU - Hur, Dae Young

AU - Kim, Daejin

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Chemotherapy agents have adverse immunotherapeutic effects secondary to inhibition of hematopoietic stem cell proliferation, particularly in committed lymphoblast. Certain anti-cancer drugs have immuno-modulatory properties, although mechanisms are still not fully understood. In the current study, we explored the effects of doxorubicin on peripheral blood CD4+ and CD8+ T-cell responses pre- and post-stimulation. Doxorubicin treatment alone had no effects on peripheral blood T lymphocytes and regulatory T-cells in vivo and in vitro. However, CD4+ T-cells were resistant to doxorubicin and demonstrated more robust proliferation than CD8+ T-cells after doxorubicin pre-treatment. CD40 ligand and 4-1BB expression on the surface of CD4+ T-cells were increased after TCR-ligation activation; however, expression on CD8+ T-cells was not increased. Dendritic cells cultured in the presence of activated CD4+ T-cells pre-treated with doxorubicin had greater survival rates than those cultured with activated CD8+ T-cells. Doxorubicin pre-treatment followed by anti-CD3ε + anti-4-1BB activation led to proliferation of CD4+ T-cells and no proliferative effects on CD8+ T-cells. Our results collectively suggest that doxorubicin pre-treatment in cancer patients may be a more effective way to enhance anti-cancer immune responses by increased antigen-specific CD4+ Th1 immune responses.

AB - Chemotherapy agents have adverse immunotherapeutic effects secondary to inhibition of hematopoietic stem cell proliferation, particularly in committed lymphoblast. Certain anti-cancer drugs have immuno-modulatory properties, although mechanisms are still not fully understood. In the current study, we explored the effects of doxorubicin on peripheral blood CD4+ and CD8+ T-cell responses pre- and post-stimulation. Doxorubicin treatment alone had no effects on peripheral blood T lymphocytes and regulatory T-cells in vivo and in vitro. However, CD4+ T-cells were resistant to doxorubicin and demonstrated more robust proliferation than CD8+ T-cells after doxorubicin pre-treatment. CD40 ligand and 4-1BB expression on the surface of CD4+ T-cells were increased after TCR-ligation activation; however, expression on CD8+ T-cells was not increased. Dendritic cells cultured in the presence of activated CD4+ T-cells pre-treated with doxorubicin had greater survival rates than those cultured with activated CD8+ T-cells. Doxorubicin pre-treatment followed by anti-CD3ε + anti-4-1BB activation led to proliferation of CD4+ T-cells and no proliferative effects on CD8+ T-cells. Our results collectively suggest that doxorubicin pre-treatment in cancer patients may be a more effective way to enhance anti-cancer immune responses by increased antigen-specific CD4+ Th1 immune responses.

KW - 4-1BB

KW - CD4

KW - CD40 ligand

KW - Doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=70350572330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350572330&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2009.09.008

DO - 10.1016/j.intimp.2009.09.008

M3 - Article

C2 - 19778641

AN - SCOPUS:70350572330

VL - 9

SP - 1530

EP - 1539

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 13-14

ER -